Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

41.38
+0.99002.45%
Post-market: 41.380.00000.00%16:10 EST
Volume:611.41K
Turnover:25.27M
Market Cap:3.20B
PE:-10.65
High:41.75
Open:41.09
Low:40.80
Close:40.39
52wk High:46.60
52wk Low:26.74
Shares:77.28M
Float Shares:71.60M
Volume Ratio:0.90
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8866
EPS(LYR):-3.0083
ROE:-45.14%
ROA:-29.51%
PB:5.72
PE(LYR):-13.76

Loading ...

Xenon (XENE) Receives a Buy from J.P. Morgan

TIPRANKS
·
Jan 20

Xenon Pharmaceuticals Grants Equity Inducement Options to New Employees

Reuters
·
Jan 17

Press Release: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Jan 17

Xenon Pharmaceuticals: Undervalued ‘Pipeline-in-a-Drug’ Story with Blockbuster Potential Ahead of Key 2026 Readouts

TIPRANKS
·
Jan 14

Xenon Pharmaceuticals: Advancing Late-Stage Epilepsy and Depression Programs and Expanding NaV1.7/Kv7 Pipeline Support Buy Rating and $55 Target

TIPRANKS
·
Jan 13

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Xenon (XENE)

TIPRANKS
·
Jan 11

Xenon Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Jan 09

Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares

Reuters
·
Jan 03

Biohaven Misses The Mark In Depression Trial, Stock Falls

Benzinga_recent_news
·
Dec 26, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks

Reuters
·
Dec 17, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse

Reuters
·
Dec 17, 2025

BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026

Reuters
·
Dec 17, 2025

BRIEF-Eles Says Xenon Increases to 2.95 Eur/Shr Its Offer Price For Eles Bid

Reuters
·
Dec 15, 2025

BRIEF-Eles Says Market Regulator Consob Has Approved Xenon Offer Document

Reuters
·
Dec 15, 2025

Xenon Pharmaceuticals Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Dec 12, 2025

Xenon Pharmaceuticals CEO Ian Mortimer Reports Disposal of Common Shares

Reuters
·
Dec 10, 2025

Xenon Pharmaceuticals Reports 48-Month Azetukalner Study Shows 90.9% Seizure Reduction in Epilepsy Patients

Reuters
·
Dec 05, 2025

Xenon Pharmaceuticals Grants Equity Inducements to New Employees

Reuters
·
Dec 05, 2025

Press Release: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Dec 05, 2025

Xenon Pharmaceuticals CEO Ian Mortimer Reports Sale of Common Shares

Reuters
·
Dec 04, 2025